We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protherics (MM) | NASDAQ:PTIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.30 | 0 | 01:00:00 |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
10 July 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .
The Registrant is furnishing a copy of its announcements as reported to the Company Announcements Office of the London Stock Exchange.
Protherics PLC
Notification of Director’s Interests
London, UK; Brentwood, TN, US: 10 July 2008 – Protherics PLC
(“Protherics” or the “Company”), the international
biopharmaceutical company focused on critical care and cancer, in accordance with Sections
3.1.4R of the FSA Disclosure and Transparency Rules, announces that 916,202 ordinary shares
(the “Shares”) were issued to Jacques Gonella, Non-executive Director of
Protherics, on 9 July 2008 following their admission to the Official List of the Financial
Services Authority.
The Shares form part of the allotment of 1,741,911 ordinary shares (details of which are
contained in the Company’s announcement dated 4 July 2008) made pursuant to the
MacroMed Acquisition Agreement (the “Agreement”) approved by shareholders at
the Company’s Extraordinary General Meeting held on 3 January 2007. Details of the
Agreement are contained in the Company’s announcement dated 7 December 2006. In
accordance with the Agreement the issue price of the shares is 69.69 pence per share.
Following the issuance of the Shares, Dr Gonella holds a beneficial interest in 9,162,017
ordinary shares in the Company representing 2.677% of the issued share capital of
342,159,034 ordinary shares.
| Ends |
For further information please contact:
Protherics |
|
Nick Staples, Director of Corporate Affairs |
+44 (0) 7919 480510 |
Julie Vickers, Company Secretary |
+44 (0)1928 518010 |
Financial Dynamics – press enquiries |
|
London: Ben Atwell, Lara Mott |
+44 (0) 20 7831 3113 |
New York: John Capodanno |
+1 212 850 5600 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PROTHERICS PLC |
||||||||
Date: 10 July 2008 |
By: |
/s/ Rolf Soderstrom |
||||||
Rolf Soderstrom |
||||||||
Finance Director |
1 Year Protherics Chart |
1 Month Protherics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions